HANGZHOU DAC BIOTECHNOLOGY Co., LTD. is a national high-tech enterprise established in December 2012. The management of the company is an entrepreneurial and innovative team of overseas high-level talents introduced by Hangzhou Economic and Technological Development Zone (HEDA, now Hangzhou Qiantang New District).
     The company was founded by several senior scientists who worked in the United States and returned to China full-time. It is committed to the research and development, production, clinical trials and marketing of monoclonal antibody-drug conjugate (ADC) biologics targeting advanced cancers.